Dr. Amir Agha, MD
What this data tells you about Dr. Agha
Dr. Amir Agha is a rheumatology in Panama City, FL, with 18 years in practice. Based on federal Medicare data, Dr. Agha performed 330,672 Medicare services across 3,799 unique beneficiaries.
Between the years covered by Open Payments, Dr. Agha received a total of $7,779 from 30 pharmaceutical and/or device companies across 486 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Agha is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 76,000 | $4 | $12 |
| Joint lubricant injection (Gel-Syn) | 57,628 | $1 | $3 |
| Tocilizumab injection (Actemra) | 56,110 | $5 | $8 |
| Golimumab infusion (Simponi Aria) | 40,616 | $11 | $35 |
| Abatacept infusion (Orencia) | 39,725 | $34 | $78 |
| Romosozumab injection (Evenity) for osteoporosis | 28,350 | $8 | $13 |
| Denosumab injection (Prolia/Xgeva) | 17,880 | $18 | $28 |
| Injection, rituximab, 10 mg | 3,600 | $63 | $143 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 2,350 | $30 | $180 |
| Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | 1,220 | $48 | $100 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 915 | $54 | $117 |
| Complete ultrasound scan of joint | 852 | $39 | $132 |
| Office visit, established patient (30-39 min) | 836 | $92 | $164 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 822 | $46 | $106 |
| Injection, methylprednisolone acetate, 40 mg | 644 | $6 | $10 |
| Office visit, established patient (20-29 min) | 515 | $62 | $112 |
| Injection, ketorolac tromethamine, per 15 mg | 504 | $0 | $8 |
| Joint injection, major joint | 410 | $49 | $93 |
| Administration of chemotherapy into vein, 1 hour or less | 346 | $93 | $207 |
| Drug injection, under skin or into muscle | 339 | $9 | $25 |
| New patient office visit (45-59 min) | 223 | $116 | $250 |
| Administration of chemotherapy into vein, each additional hour | 146 | $21 | $45 |
| Aspiration and/or injection of fluid from small joint using ultrasound guidance | 134 | $62 | $150 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 105 | $76 | $140 |
| Injection of additional new drug or substance into vein | 101 | $12 | $55 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 75 | $3 | $8 |
| New patient office visit (30-44 min) | 65 | $73 | $164 |
| Injection, zoledronic acid, 1 mg | 59 | $7 | $20 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose | 55 | $60 | $122 |
| Blood draw (venipuncture) | 26 | $5 | $5 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 21 | $4 | $100 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Agha is a mixed practice specialist, with above-average Medicare volume (top 2% in FL), and low-engagement industry engagement, with 18 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Agha experienced with certolizumab injection (cimzia)?
Does Dr. Agha receive payments from pharmaceutical companies?
How do Dr. Agha's costs compare to other rheumatologys in Panama City?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology